November 20th 2024
SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.
Biologic Drug Manufacturing Capacity on the Agenda for INTERPHEX 2019 Keynote Series
April 3rd 2019Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Perfusion-Enabled Bioreactors
September 4th 2018A collaboration integrates Sartorius Stedim Biotech’s BIOSTAT STR bioreactors and Repligen’s XCell ATF cell-retention control technology to create simplified, scalable equipment for intensified cell culture.